HK Stock Market Move | SHINEWAY PHARM (02877) rose by more than 8% in the afternoon, with a 13% year-on-year increase in net profit. It plans to distribute the first interim dividend for the year 2026.

SHINEWAY PHARM (02877) released its annual performance at noon, with its stock price rising more than 8% in the afternoon. As of the time of publication, it had increased by 7.87% to HK$9.32, with a turnover of HK$106.904 million. In terms of news, SHINEWAY PHARM announced its annual performance, with an annual revenue of RMB 3.135 billion, a year-on-year decrease of 17.0%; annual net profit was RMB 950 million, a year-on-year increase of 13.1%; earnings per share was 126 RMB cents. It declared a mid-term dividend of 43 RMB cents per share for 2026, together with a second mid-term dividend of 11 RMB cents per share for 2025, making a total dividend of 54 RMB cents per share for the 2025 fiscal year, with a payout ratio of 42.9%. The announcement stated that in 2025, the company's eight flagship products won the bid for the national Traditional Chinese Medicine (TCM) procurement alliance centralized procurement. The bid-winning products cover various areas of treatment including cardiovascular and cerebrovascular diseases, respiratory diseases, and digestive system diseases, which are the most commonly used medical insurance and essential drug varieties in clinical practice. After winning the bid for centralized procurement, the bid-winning products are more in line with the payment requirements of Diagnosis Related Groups (DRG) and Diagnosis-Related Group Payment (DIP), providing high-quality and cost-effective medication choices for more patients, further enhancing the future terminal market demand, market coverage, and greater market sales space for the company's products.